

University of Groningen

## Prediction and monitoring of chronic kidney disease

Schutte, Elise

**IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.**

*Document Version*

Publisher's PDF, also known as Version of record

*Publication date:*

2017

[Link to publication in University of Groningen/UMCG research database](#)

*Citation for published version (APA):*

Schutte, E. (2017). *Prediction and monitoring of chronic kidney disease*. [Thesis fully internal (DIV), University of Groningen]. Rijksuniversiteit Groningen.

**Copyright**

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

The publication may also be distributed here under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license. More information can be found on the University of Groningen website: <https://www.rug.nl/library/open-access/self-archiving-pure/taverne-amendment>.


**Take-down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

*Downloaded from the University of Groningen/UMCG research database (Pure): <http://www.rug.nl/research/portal>. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.*

# Chapter 12

## **Publications**



## Publications

1. Schutte E, Lambers Heerspink HJ, Lutgers HL, Bakker SJL, Vart P, Wolffenbuttel BHR, Umanath K, Lewis JB, de Zeeuw D, Gansevoort RT. Serum bicarbonate and kidney disease progression and cardiovascular outcome in patients with diabetic nephropathy: A post hoc analysis of the RENAAL (reduction of end points in Non-Insulin-dependent diabetes with the angiotensin II antagonist losartan) study and IDNT (irbesartan diabetic nephropathy trial). *American Journal of Kidney Diseases* 66(3): 450-458, 2015
2. Schutte E, Gansevoort RT, Benner J, Lutgers HL, Lambers Heerspink HJ. Will the future lie in multitude? A critical appraisal of biomarker panel studies on prediction of diabetic kidney disease progression. *Nephrol Dial Transplant* 30 Suppl 4: iv96-104, 2015
3. Liu LC, Schutte E, Gansevoort RT, van der Meer P, Voors AA. Finerenone: Third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease. *Expert Opin Investig Drugs* 24(8): 1123-1135, 2015
4. Zelle DM, Corpeleijn E, Klaassen G, Schutte E, Navis G, Bakker SJ. Fear of movement and low self-efficacy are important barriers in physical activity after renal transplantation. *PLoS One* 11(2): e0147609, 2016
5. Schutte E, de Vos LC, Lutgers HL, Lambers Heerspink HJ, Wolffenbuttel BH, Vart P, Zeebregts CJ, Gansevoort RT, Lefrandt JD. Association of skin autofluorescence levels with kidney function decline in patients with peripheral artery disease. *Arterioscler Thromb Vasc Biol* 36(8): 1709-1714, 2016
6. Boele-Schutte E, & Gansevoort RT. Measured GFR: Not a gold, but a gold-plated standard. *Nephrol Dial Transplant* 32(suppl\_2): ii180-ii184, 2017